Advances in Laboratory Medicine / Avances en Medicina de Laboratorio最新文献

{"title":"Detection capacity of small intestine bacterial or methanogen overgrowth by lactose and fructose breath testing in the adult population","authors":"Emilio José Laserna Mendieta, V. Martín Domínguez, Irene Pérez Lucendo, Inmaculada Granero Cremades, Raquel Ferreirós Martínez, Tomás Álvarez Malé, M. A. Sanz de Benito, C. Santander","doi":"10.1515/almed-2024-0115","DOIUrl":"https://doi.org/10.1515/almed-2024-0115","url":null,"abstract":"\u0000 \u0000 \u0000 Exhaled breath tests (BTs) are the main diagnostic method for fructose and lactose malabsorption/intolerance (FI and LI, respectively) and for detecting small intestine bacterial or methanogen overgrowth (SIBO/IMO). Although FI/LI-BTs may provide evidence of the presence of SIBO/IMO, there is limited literature evaluating their reliability for this purpose. The objective of this study was to assess the sensitivity and specificity of FI/LI-BTs in detecting SIBO and their concordance with SIBO-BTs in the identification of IMO.\u0000 \u0000 \u0000 \u0000 In this retrospective observational study, FI/LI-BTs and SIBO-BTs performed in the same patients within a period of 6 weeks were selected from 652 gas chromatography-based BTs.\u0000 \u0000 \u0000 \u0000 A total of 146 BTs from 67 eligible adult patients were identified. LI-BTs had higher specificity than FI-BT in detecting SIBO (93.8 % vs. 72.7 %). In contrast, FI-BTs showed higher sensitivity (60.0 % vs. 28.6 %) as FI was more frequently established in SIBO-positive patients (70 % vs. 29 %). With regard to IMO, concordance with LI-BT was 100 %, with a 27 % of false negatives on FI-BTs.\u0000 \u0000 \u0000 \u0000 Findings suggestive of SIBO or IMO on LI-BTs were highly consistent with those of SIBO-BTs. In contrast, the rate of false positives for SIBO and the rate of false negative for IMO on FI-BTs was 27 % in both cases.\u0000","PeriodicalId":7333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"5 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141921823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anomalía de Jordans en síndrome de Chanarin-Dorfman","authors":"Jorge Sánchez-Cortés, Xavier Gabaldó-Barrios","doi":"10.1515/almed-2024-0073","DOIUrl":"https://doi.org/10.1515/almed-2024-0073","url":null,"abstract":"\u0000 \u0000 \u0000 El síndrome de Chanarin-Dorfman es un síndrome raro de herencia autosómica recesiva cuya prevalencia no supera los 130 casos en el mundo.\u0000 \u0000 \u0000 \u0000 Paciente de 4 años afecto de síndrome ictiosiforme eritemato-descamativo generalizado desde los primeros días del nacimiento. En el informe de laboratorio destacó hipertransaminemia persistente en el tiempo. Entre otras pruebas complementarias, se realizó el frotis de sangre periférica (SP), revelando la presencia de múltiples vacuolas citoplasmáticas en el interior de los leucocitos polimorfonucleares (PMN) y plaquetas. Las lesiones ictiosiformes junto con la presencia de vacuolas lipídicas en los PMN de SP son signos compatibles con síndrome de Chanarin-Dorfman. El diagnóstico se confirmó mediante secuenciación genética.\u0000 \u0000 \u0000 \u0000 El síndrome de Chanarin-Dorfman está caracterizado por una mutación del gen CGI-58, el cual está implicado en el catabolismo de los triglicéridos de cadena larga almacenados en gotas lipídicas citoplasmáticas. La anomalía de Jordans es un rasgo congénito caracterizado por la presencia de abundantes vacuolas en la serie granulocítica debido a defectos en el metabolismo lipídico. En este síndrome, los triglicéridos de cadena larga se depositan en los tejidos produciendo principalmente manifestaciones dermatológicas controlables mediante la restricción de los mismos en la dieta.\u0000","PeriodicalId":7333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"25 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141801966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Espectrometría de masas en los laboratorios clínicos de proteínas","authors":"Carmen Mugueta, Á. González, Sara Deza, Cristina Agulló Roca, T. Contreras, Noemí Puig, Nerea Varo","doi":"10.1515/almed-2024-0071","DOIUrl":"https://doi.org/10.1515/almed-2024-0071","url":null,"abstract":"","PeriodicalId":7333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"69 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141268218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impacto de la intervención del laboratorio en la caracterización de la hipervitaminosis b12 en la práctica asistencial","authors":"Sara Fernández-Landázuri, Ramón Baeza-Trinidad, Iván Bernardo González","doi":"10.1515/almed-2024-0010","DOIUrl":"https://doi.org/10.1515/almed-2024-0010","url":null,"abstract":"\u0000 \u0000 \u0000 El hallazgo de hipervitaminosis B12 (HB12) no justificado en pacientes asintomáticos desencadena consultas médicas y pruebas diagnósticas, a fin de determinar la etiología. Nuestro objetivo fue probar la eficacia de la intervención del laboratorio en la detección y eliminación de inmunocomplejos con vitamina B12 en la práctica clínica, así como su impacto económico.\u0000 \u0000 \u0000 \u0000 Es un estudio retrospectivo y longitudinal diseñado para evaluar la estrategia del laboratorio para detectar macrovitamina B12 (macro-B12) en aquellos pacientes con HB12 mayor a 1.000 pg/mL. Se compararon las características clínicas de los pacientes con HB12 derivados a las consultas de Medicina Interna (MI) en el año anterior y posterior a la implantación de la estrategia y se calcularon los costes asistenciales generados en el año de seguimiento de los pacientes.\u0000 \u0000 \u0000 \u0000 La prevalencia de HB12 en el periodo previo y posterior a la implantación fue del 3,9 % y 3 %, respectivamente. La macro-B12 fue responsable del 25 % de la HB12 iniciales detectadas. El número de pacientes con HB12 derivados a las consultas de MI se redujo en el 41 % tras la implantación, traduciéndose en un ahorro de más de 5.000€.\u0000 \u0000 \u0000 \u0000 La intervención del laboratorio de detección de macro-B12 tiene un claro beneficio asistencial y económico en la práctica clínica.\u0000","PeriodicalId":7333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"29 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141271026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aplicaciones del metaverso en medicina y atención sanitaria","authors":"Tim Hulsen","doi":"10.1515/almed-2024-0004","DOIUrl":"https://doi.org/10.1515/almed-2024-0004","url":null,"abstract":"\u0000 El metaverso es un mundo virtual, aún en proceso de desarrollo, que permite a las personas interactuar entre ellas, así como con objetos digitales de una forma más inmersiva. Esta innovadora herramienta aúna las tres principales tendencias tecnológicas: la telepresencia, el gemelo digital y la cadena de bloques. La telepresencia permite a las personas “reunirse” de manera virtual, aunque se encuentren en distintos lugares. El gemelo digital es el equivalente virtual y digital de un paciente, dispositivo médico o incluso de un hospital. Por último, la cadena de bloques puede ser utilizada por los pacientes para almacenar sus informes médicos personales de forma segura. En medicina, el metaverso podría tener distintas aplicaciones: (1) consultas médicas virtuales; (2) educación y formación médica; (3) educación del paciente; (4) investigación médica; (5) desarrollo de medicamentos; (6) terapia y apoyo; (7) medicina de laboratorio. El metaverso permitiría una atención sanitaria más personalizada, eficiente y accesible, mejorando así los resultados clínicos y reduciendo los costes de atención médica. No obstante, la implementación del metaverso en medicina y atención sanitaria requerirá una cuidadosa evaluación de los aspectos éticos y de privacidad, así como técnicos, sociales y jurídicos. En términos generales, el futuro del metaverso en el campo de la medicina parece prometedor, aunque es necesario desarrollar nuevas leyes que regulen específicamente el metaverso, con el fin de superar sus posibles inconvenientes.","PeriodicalId":7333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"4 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139958917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uso de glucómetros durante la prueba de tolerancia oral a la glucosa en niños para el diagnóstico de prediabetes y diabetes. Estudio comparativo","authors":"Blanca Fabre-Estremera, Estéfani Martínez-Chávez, Marta Manzano Ocaña, Atilano Carcavilla Urquí, María de los Ángeles Morales Sánchez, Inmaculada Pinilla Tejado, Isabel González-Casado, Itsaso Losantos García, Pilar Fernández-Calle, A. B. Soto, Paloma Oliver","doi":"10.1515/almed-2024-0017","DOIUrl":"https://doi.org/10.1515/almed-2024-0017","url":null,"abstract":"\u0000 \u0000 \u0000 A pesar de que las guías clínicas aún no recomiendan el uso de glucómetros en el lugar de asistencia al paciente (POCT) con fines diagnósticos, la prestación analítica de estos dispositivos ha mejorado significativamente. En este contexto, evaluamos la precisión analítica y la concordancia diagnóstica de los glucómetros POCT durante la prueba de tolerancia oral a la glucosa (PTOG), para el diagnóstico de prediabetes y diabetes en un estudio comparativo.\u0000 \u0000 \u0000 \u0000 En este estudio prospectivo observacional, fueron reclutados pacientes pediátricos con indicación de PTOG, derivados a la Unidad de Diabetes entre diciembre de 2020 y septiembre de 2021. Durante la prueba funcional, se midió la glucemia en sangre venosa con dos glucómetros POCT (uno con conectividad y otro sin conectividad) y en el laboratorio central.\u0000 \u0000 \u0000 \u0000 El estudio incluyó 98 pacientes. Observamos una elevada correlación entre los glucómetros y el laboratorio (coeficiente de Pearson=0,912 para el glucómetro sin conectividad y 0,950 para el glucómetro con conectividad). El tiempo de respuesta de la PTOG disminuyó significativamente (mediana glucómetro con conectividad: 2,02 horas [rango intercuartílico: 2,00–2,07], laboratorio: 11,63 horas [6,09–25,80]), con un coste global similar. La concordancia diagnóstica entre el glucómetro con conectividad y el laboratorio fue del 71,1 % (IC 95 % 61,5–79,2). La decisión clínica hubiera sido la misma en el 92,8 % de los casos, aunque no se habría indicado tratamiento en cuatro pacientes (4,1 %).\u0000 \u0000 \u0000 \u0000 Durante las PTOG, los glucómetros POCT muestran una elevada correlación y una concordancia diagnóstica aceptable con el laboratorio, ofreciendo además el glucómetro con conectividad una reducción significativa del tiempo de respuesta, sin incrementar los costes. No obstante, dado que en algún caso podría haber un impacto clínico grave, los glucómetros POCT aún no deben ser utilizados con fines diagnósticos.\u0000","PeriodicalId":7333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"1 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139958554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical, biochemical, and molecular profiles of three Sri Lankan neonates with pyruvate carboxylase deficiency","authors":"E. Jasinge, M. Fernando, N. Indika, P. Ratnayake, Nalin Gamaathige, Ratnanathan Ratnaranjith, Sabine Schroeder, P. Jones, Skrahina Volha, Subhashinie Jayasena, Anusha Varuni Gunaratna, Asitha Niroshana Bandara Ekanayake, Arndt Rolfs","doi":"10.1515/almed-2023-0102","DOIUrl":"https://doi.org/10.1515/almed-2023-0102","url":null,"abstract":"Abstract Objectives Pyruvate carboxylase, a mitochondrial enzyme, catalyses the conversion of glycolytic end-product pyruvate to tricarboxylic acid cycle intermediate, oxaloacetate. Rare pyruvate carboxylase deficiency manifests in three clinical and biochemical phenotypes: neonatal onset type A, infantile onset type B and a benign C type. The objective of this case series is to expand the knowledge of overlapping clinical and biochemical phenotypes of pyruvate carboxylase deficiency. Case presentation We report three Sri Lankan neonates including two siblings, of two unrelated families with pyruvate carboxylase deficiency. All three developed respiratory distress within the first few hours of birth. Two siblings displayed typical biochemical findings reported in type B. The other proband with normal citrulline, lysine, moderate lactate, paraventricular cystic lesions, bony deformities, and a novel missense, homozygous variant c.2746G>C [p.(Asp916His)] in the PC gene, biochemically favoured type A. Conclusions Our findings indicate the necessity of prompt laboratory investigations in a tachypneic neonate with coexisting metabolic acidosis, as early recognition is essential for patient management and family counselling. Further case studies are required to identify overlapping symptoms and biochemical findings in different types of pyruvate carboxylase deficiency phenotypes.","PeriodicalId":7333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139380106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determination of ertapenem in plasma and ascitic fluid by UHPLC-MS/MS in cirrhotic patients with spontaneous bacterial peritonitis","authors":"Raúl Rigo-Bonnin, Alberto Amador, María Núñez-Gárate, Virgínia Mas-Bosch, A. Padulles, S. Cobo-Sacristán, José Castellote","doi":"10.1515/almed-2023-0168","DOIUrl":"https://doi.org/10.1515/almed-2023-0168","url":null,"abstract":"Abstract Objectives Spontaneous bacterial peritonitis is a frequent severe complication in cirrhotic patients with ascites. Carbapenem antibiotics are currently the treatment of choice for patients with hospital-acquired or healthcare-related infections. However, there is limited evidence available on the efficacy of ertapenem in cirrhotic patients with spontaneous bacterial peritonitis. As a result, the pharmacokynetics and pharmacodynamics of this antibiotic are still unknown. The objective of this study was to develop and validate measurement procedures based on liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) to determine ertapenem concentrations in plasma and ascitic fluid. Methods Samples were pretreated by acetronile protein-precipitation. Chromatographic separation is performed on a C18 reversed-phase Acquity®-UPLC®-BEHTM column (2.1 × 100 mm id, 1.7 µm) using a non-linear gradient of water/acetonitrile containing 0.1 % of formic acid at a flow rate of 0.4 mL/min. Ertapenem and its internal standard (ertapenem-D4) are detected by tandem mass spectrometry using positive electrospray ionization and multiple reaction monitoring, and using 476.2 → 346.0/432.2 as mass transition for ertapenem and 480.2 → 350.0 for its internal standard. Results No significant interferences or carry-over contamination were observed. Imprecisions, absolute relative bias, matrix effects and normalized recoveries were ≤14.5 %, ≤9.3 % (92.8–104.5) % and (98.8–105.8) %, respectively. Chromatographic measurement procedures were linear from (0.50–100) mg/L. Conclusions The measurement procedures based on UHPLC-MS/MS developed and validated in this study could be useful in pharmacokynetic and pharmacodynamic studies in subjects with liver cirrhosis who develop spontaneous bacterial peritonitis treated with ertapenem.","PeriodicalId":7333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"107 32","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138958772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"La osteocalcina se asocia con la densidad mineral ósea y los polimorfismos del gen VDR en la diabetes tipo 1 y 2","authors":"C. Ruiz, Nerea Varo Cenarruzabeitia, Miriam Martínez Villanueva, Antonio M. Hernández Martínez, J. A. Noguera Velasco","doi":"10.1515/almed-2023-0158","DOIUrl":"https://doi.org/10.1515/almed-2023-0158","url":null,"abstract":"Resumen Objetivos El metabolismo óseo se encuentra alterado en la diabetes mellitus (DM). El objetivo de este estudio es evaluar la relación entre los marcadores de remodelado óseo (MRO), los polimorfismos en el gen receptor de la vitamina D (VDR) y la densidad mineral ósea (DMO) en la DM tipo 1 (T1D) y tipo 2 (T2D). Métodos Se incluyó a 165 pacientes (53 T1D y 112 T2D). La DMO se midió mediante absorciometría de rayos X de energía dual (DEXA). Se realizó un análisis de la osteocalcina (OC) en plasma, beta-CrossLaps (β-CTX), propéptido aminoterminal del procolágeno tipo 1 (P1NP) y los polimorfismos en el gen VDR. Resultados Se incluyó a 53 pacientes con T1D (41 años (31–48)) y 112 con T2D (60 años [51–66]). No se observaron diferencias estadísticamente significativas en relación a la DMO. Los pacientes con T1D presentaron niveles superiores de OC (p<0,001) y P1NP (p<0,001). Las áreas bajo la curva para la predicción de patología ósea para la OC fueron 0,732 (p=0,038) en T1D y 0,697 (p=0,007) en T2D. Se observó una relación estadísticamente significativa entre el alelo A de BsmI (p=0,03), el alelo A de ApaI (p=0,04) y el alelo C de Taql (p=0,046) y una menor DMO. Así mismo, se encontró una correlación significativa entre los niveles elevados de OC y el alelo G de BsmI (p=0,044), el alelo C de ApaI (p=0,011), el alelo T de Taql (p=0,006) y el alelo C de FokI (p=0,004). Conclusiones El elevado valor predictivo negativo del punto de corte de la OC indica que la OC podría ser útil a la hora de descartar el riesgo de pérdida ósea, lo que permitiría diseñar un tratamiento personalizado para prevenir dicha patología.","PeriodicalId":7333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"138 24","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139003930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The hidden cross talk between bone and tissues through bone turnover","authors":"M. González-Casaus","doi":"10.1515/almed-2023-0160","DOIUrl":"https://doi.org/10.1515/almed-2023-0160","url":null,"abstract":"Abstract Bone is more than a reservoir of calcium and phosphorus. Its lacuno-canalicular arrangement provides an important pathway for exchange with circulation and currently, the skeleton is considered a large endocrine organ with actions that go beyond the control of calcium-phosphorus balance mediated by fibroblastic growth factor 23 (FGF23). Parallel to the modulating effect of adipokines on bone turnover, certain bone proteins, such as osteocalcin and sclerostin, play a counter-regulatory role on energy metabolism, probably in an attempt to ensure its high energy requirement for bone turnover. In this crosstalk between bone and other tissues, especially with adipose tissue, canonical Wnt/β-catenin signaling is involved and therefore, sclerostin, an osteocyte derived protein that inhibits this signalling, emerges as a potential biomarker. Furthermore, its involvement in diverse pathologic conditions supports sclerostin as a therapeutic target, with an anti-sclerostin antibody recently approved in our country for the treatment of osteoporosis. This review addresses the endocrine nature of bone, the role of osteocalcin, and specially, the regulatory and modulatory role of sclerostin on bone turnover and energy homeostasis through its inhibitory effect on canonical Wnt/β-catenin signaling, as well as its potential utility as a biomarker.","PeriodicalId":7333,"journal":{"name":"Advances in Laboratory Medicine / Avances en Medicina de Laboratorio","volume":"31 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138633117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}